Disease Overview：Pulmonary Embolism（PE）
Pulmonary embolism (PE) is a life-threatening cardiovascular condition caused by the obstruction of one or more pulmonary arteries—most commonly by thrombi originating from deep vein thrombosis (DVT) in the lower extremities. Clinical presentation ranges from asymptomatic to sudden dyspnea, pleuritic chest pain, hemoptysis, tachycardia, and, in severe cases, hemodynamic instability or cardiac arrest. Risk factors include prolonged immobility, recent surgery, malignancy, pregnancy, oral contraceptive use, and inherited thrombophilias. Diagnosis relies on clinical assessment (e.g., Wells score), D-dimer testing, and confirmatory imaging—primarily CT pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) scintigraphy. Acute management centers on anticoagulation (e.g., low-molecular-weight heparin, direct oral anticoagulants), with advanced interventions—including catheter-directed thrombolysis, surgical embolectomy, or inferior vena cava filter placement—reserved for high-risk or submassive PE with right ventricular dysfunction.
China offers distinct advantages for PE treatment: its leading cardiovascular centers—such as Fuwai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—combine internationally trained interventional cardiologists and pulmonologists with state-of-the-art hybrid operating suites, 3D rotational angiography, and AI-enhanced CTPA interpretation. Success rates for acute PE intervention exceed 92% in tertiary referral centers, supported by robust outcome registries and multidisciplinary PE response teams. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or accreditation standards (JCI- or CNAS-certified facilities). As a dedicated medical tourism agency, we facilitate seamless international care—handling hospital referrals, pre-arrival diagnostic coordination, transparent all-inclusive pricing (covering diagnostics, procedure, ICU stay, and follow-up), visa support, and bilingual clinical liaison services—ensuring continuity, clarity, and confidence throughout the patient journey.
Pulmonary Embolism: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pulmonary Embolism (Cardiology Department)
Non-Surgical / Conservative Management
*Indicated for low- to intermediate-risk PE without hemodynamic instability, contraindications to anticoagulation, or stable chronic thromboembolic pulmonary hypertension (CTEPH).*
- •Anticoagulation Therapy (First-Line)
- *Itemized Costs (USD, Grade 3A Hospital):* - LMWH (enoxaparin, 7-day course): $180–$240 - DOAC (rivaroxaban/apixaban, 3-month course): $320–$460 - Warfarin + INR monitoring (3 months): $110–$150 (includes 12 PT/INR tests @ $9 each) - *Required Baseline Exams:* D-dimer ($22), CBC ($12), renal function ($18), liver panel ($24), ECG ($15), chest X-ray ($28) → Total: $119
Surgical / Procedural / Interventional Options
*Eligibility strictly requires high-risk PE (systolic BP <90 mmHg, cardiac arrest, or persistent shock) or intermediate-high-risk with clinical deterioration despite anticoagulation.*
- •Catheter-Directed Thrombolysis (CDT)
- *Procedure Fee:* $3,800–$5,200 (includes catheterization, urokinase/tPA infusion, ICU monitoring × 48h) - *Preoperative Workup:* CT pulmonary angiography ($145), echocardiogram ($85), arterial blood gas ($26), coagulation panel ($32) → Total: $288
- •Surgical Pulmonary Embolectomy
- *Procedure Fee:* $8,900–$11,400 (CPB, sternotomy, ICU × 5 days) - *Preoperative Workup:* Same as CDT + transthoracic echo ($85), ABG ($26), crossmatch ($42) → Total: $375
Special / Complex Condition Management
- •Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- *Balloon Pulmonary Angioplasty (BPA):* $4,500–$6,300 per session, typically 2–4 sessions ($9,000–$25,200 total)
Quick Selection Guide
- •Young, Low-Risk, Budget-Conscious (<60 yrs, no comorbidities): DOAC monotherapy ($320–$460) + baseline labs ($119)
- •Elderly, Renal Impairment (eGFR 30–60 mL/min): LMWH + renal-adjusted dosing ($240) + extended monitoring ($119)
- •High-Risk, Shocked Patient: Immediate CDT ($3,800–$5,200) — avoids surgical risk and reduces mortality vs. delayed surgery
- •CTEPH Confirmed: PEA at specialized center ($14,200–$17,600) — superior long-term survival vs. medical therapy alone
- •Contraindicated to All Thrombolytics/Surgery: Inferior vena cava filter placement ($2,100–$2,900) + lifelong anticoagulation ($320–$460/year)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pulmonary Embolism Medical Vacation Packages
Curated transparent all-inclusive packages combining Pulmonary Embolism treatment with China top medical destinations:
